Live Breaking News & Updates on Marka Mcpartland

Stay updated with breaking news from Marka mcpartland. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on trackPALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) $VTGN #mentalhealth Vistagen (Nasdaq: VTGN), a late clinical-stag. ....

United States , Shawn Singh , Marka Mcpartland , Company Phase , Company Quarterly Report On Form , International Number Toll , Women Health Indications , Exchange Commission , Chief Executive Officer , Nasal Spray , Acute Treatment , Social Anxiety Disorder , Subjective Units , Distress Scale , Drug Application , Major Depressive Disorder , Vasomotor Symptoms , Hot Flashes , Quarter Financial , Dial In Number , Annual Report , Quarterly Report ,

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Marka Mcpartland , Nate Hitchings , Vistagen Fiscal Year , Update Conference Call , Toll Free , International Dial In , Vice President , Investor Relations ,

VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March


VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Shawn Singh, VistaGen’s Chief Executive Officer, will participate in the following investor conferences in March:
Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference
Dates:
 
Format:
Website:
 
Date:
Format:
 
About VistaGen
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s three dru ....

Jason Mccarthy , Shawn Singh , Marka Mcpartland , Maxim Group , Vistagen Therapeutics Inc , Company Contact , Research Analyst , Vistagen Therapeutics , Chief Executive Officer , Inaugural Emerging Growth Virtual , Gen Therapeutics , ஜேசன் ம்க்கார்தீ , ஷான் சிங் , மார்க்கா மக்பார்ட்‌ல்யாஂட் , மாக்சிம் குழு , நிறுவனம் தொடர்பு , ஆராய்ச்சி ஆய்வாளர் , தலைமை நிர்வாகி அதிகாரி , தொடக்க வளர்ந்து வருகிறது வளர்ச்சி மெய்நிகர் , கேன் சிகிச்சை ,